Unity Biotechnology, Inc. (UBX)

NASDAQ: UBX · IEX Real-Time Price · USD

1.500

-0.010 (-0.66%)

At close: Apr 19, 2024, 4:00 PM

1.540

+0.040 (2.67%)

After-hours: Apr 19, 2024, 7:08 PM EDT

Unity Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	0	0.24	4.78	0	0	0	0	0
Revenue Growth (YoY)	-	-95.07%	-	-	-	-	-	-
Gross Profit	0	0.24	4.78	0	0	0	0	0
Selling, General & Admin	18.97	20.95	23.06	24.03	20.05	16.02	9.62	5.14
Research & Development	20.1	36.86	38.39	67.31	70.96	58.91	37.37	13.71
Other Operating Expenses	5.6	0	0	2.6	-1.35	4.54	0	0
Operating Expenses	44.67	57.81	61.45	93.93	89.65	79.47	46.99	18.84
Operating Income	-44.67	-57.57	-56.67	-93.93	-89.65	-79.47	-46.99	-18.84
Interest Expense / Income	2.45	3.56	3.18	1.29	0	0	0	2.18
Other Expense / Income	-7.26	-16.66	0.88	-1.38	-7.47	-3.07	-2.33	9.38
Pretax Income	-39.86	-44.47	-60.73	-93.84	-82.18	-76.4	-44.66	-30.4
Net Income	-39.86	-44.47	-60.73	-93.84	-82.18	-76.4	-44.66	-30.4
Shares Outstanding (Basic)	15	9	6	5	4	3	0	0
Shares Outstanding (Diluted)	15	9	6	5	4	3	0	0
Shares Change	55.60%	70.10%	9.73%	16.60%	54.32%	784.12%	20.08%	-
EPS (Basic)	-2.70	-4.68	-10.88	-18.45	-18.80	-27.00	-139.70	-114.20
EPS (Diluted)	-2.70	-4.68	-10.88	-18.45	-18.80	-27.00	-139.70	-114.20
Free Cash Flow	-36.98	-52.13	-45.26	-78.98	-74.01	-57.89	-40.05	-18.64
Free Cash Flow Per Share	-2.50	-5.49	-8.11	-15.53	-16.96	-20.48	-125.24	-70.01
Gross Margin	-	100.00%	100.00%	-	-	-	-	-
Operating Margin	-	-24394.92%	-1184.47%	-	-	-	-	-
Profit Margin	-	-18842.80%	-1269.34%	-	-	-	-	-
Free Cash Flow Margin	-	-22089.83%	-945.97%	-	-	-	-	-
EBITDA	-36.23	-38.73	-54.67	-89.1	-79.51	-74.22	-43.35	-28.07
EBITDA Margin	-	-16411.44%	-1142.73%	-	-	-	-	-
Depreciation & Amortization	1.18	2.18	2.88	3.45	2.66	2.18	1.3	0.15
EBIT	-37.41	-40.91	-57.55	-92.55	-82.18	-76.4	-44.66	-28.22
EBIT Margin	-	-17335.17%	-1202.93%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).